OneSource Specialty Pharma reported a 12% year-over-year increase in revenue for Q2FY26, reaching $43.1 million. EBITDA surged by 37% YoY to $12.2 million, with EBITDA margin expanding to 28%. The company’s adjusted PAT turned profitable at $5.2 million. OneSource is also progressing with a proposed acquisition to strengthen its global footprint and capabilities, expecting closure by December 2026.
Q2FY26 Financial Highlights
OneSource Specialty Pharma has announced its financial results for the second quarter of fiscal year 2026, showcasing significant growth in revenue and profitability:
- Revenue: Increased by 12% year-over-year to $43.1 million.
- EBITDA: Rose by 37% year-over-year to $12.2 million, representing a 28% margin.
- Adjusted PAT: Improved from a loss to a profit of $5.2 million.
The company highlighted that the revenue increase was driven by MSAs execution and sales from its IP-led base business. DDC capacity addition is accelerating to support upcoming customer launches.
Proposed Acquisition
OneSource is set to strengthen its global presence through a proposed acquisition. As of September 30, 2025, the net debt for the incoming business stands at $11.5 million, expected to trend towards $7-8 million.
The acquisition is expected to add approximately $21 million in revenue and $7 million in EBITDA, with a 32% EBITDA margin (proforma). Key benefits include securing new partnerships, establishing a de-risked European platform for DDCs, gaining a wider base of experience in RTU and 505(b)(2) products, and expanding global reach for regional partners. The company anticipates closure by December 2026.
Business Outlook and Strategic Initiatives
OneSource is focusing on several key areas to drive future growth:
- DDC Capacities: Expanding capacity to support upcoming commercial supplies.
- Biologics: Seeing a significant boost in its biologics funnel through customer outreach and industry tailwinds, with approximately a 4x increase in the biologics funnel compared to FY25.
- Sustainability: Progressing towards stronger governance with integrated reporting and improved disclosure practices.
FY28 Financial Targets
The company has revised its FY28 financial outlook, projecting revenue of $400 million from organic growth, with an EBITDA margin of approximately 40%. Including the recently proposed acquisition, OneSource anticipates revenue exceeding $500 million with a targeted ROCE above 50%, a steady-state EBITDA margin of around 40%, and net debt-to-EBITDA below 1.5x.
Source: BSE
